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Background: Monocytes and macrophages produce interleukin (IL)-10, an immunoregulatory cytokine and a
potent therapeutic tool for immune disorders. Augmentation of IL-10 production with a concomitant reduction of
proinflammatory cytokines in macrophages in vitro is attained by doubly stimulating the cells with a toll-like receptor
ligand and immunoglobulin (Ig)G immune complexes, a response known as that of regulatory (or alternatively
activated/M2) macrophages. However, it has not been explored sufficiently how such a regulatory response
could be exploited for anti-inflammation. Our objective is to find a potential way or condition for augmenting
IL-10 by monocytes/macrophages in vivo and in vitro.
Results: We show that platelets, when they are opsonized with IgG, can convert human peripheral blood
circulating monocytes to IL-10-producing regulatory monocytes in vitro and also in a murine in vivo model.
Co-culturing of platelets and monocytes in the presence of anti-integrin IgG and a bacterial lipopolysaccharide
augmented IL-10 production via a direct interaction between platelets and monocytes. This novel way of
enhancing IL-10 was mediated by activating-type Fc receptors for IgG.
Conclusion: These findings indicate that the IgG-bound platelet-induced conversion of monocytes to regulatory
cells might provide a novel strategy for controlling inflammation.
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Monocytes in the bloodstream and macrophages in tissues
play important roles in immunity not only as inflamma-
tory initiators by releasing a series of proinflammatory cy-
tokines and chemokines [1], but also as regulators of the
inflammation by producing a potent anti-inflammatory or
immunoregulatory cytokine, IL-10 [2-6]. Recently, the IL-
10-mediated anti-inflammatory mechanism of monocytes/
macrophages as well as of many other leukocytes such
as regulatory T cells and IL-10-producing B cells has
attracted much interest because of its potential thera-
peutic benefit for immune disorders including inflamma-
tion and autoimmune diseases. Therefore, it is important to
find an efficient way to induce IL-10 from such leukocytes,* Correspondence: tostakai@idac.tohoku.ac.jp
1Department of Experimental Immunology, Institute of Development, Aging
and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575,
Japan
Full list of author information is available at the end of the article
© 2015 Inui et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.particularly monocytes/macrophages, as a rich source of
IL-10 in the bloodstream and tissues [7-13].
One prominent IL-10-producing mechanism of monocytes/
macrophages in vitro is that of regulatory (or alternatively
activated or M2) macrophages, i.e., cells stimulated with a
TLR ligand such as LPS in conjunction with IgG-immune
complexes (IgG-ICs) like those comprising OVA and anti-
OVA IgG, or other stimuli including prostaglandins,
G-protein-coupled receptor ligands, glucocorticoids,
apoptotic cells, or IL-10 itself [14]. Signaling of the IL-10
up-regulation by LPS- and IgG-IC-stimulated macro-
phages has been revealed to involve ERK, p38, MAF, and
NF-κB [10]. Also experimentally, murine macrophages are
converted to regulatory cells via IgG-bound sheep erythro-
cytes [14,15] on simultaneous LPS stimulation. IgG-bound
Leishmania exploits the regulatory-type activation of mac-
rophages for its parasitic invasion into the macrophages,
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phages are induced in more physiologic settings.
During our testing of a series of IgG mAbs against hu-
man PBMCs as to their cytokine induction effects, we
found that some mAbs can augment IL-10 production by
PBMCs stimulated with LPS in vitro. Detailed analyses re-
vealed that the targets of these IgG mAbs were integrins
on platelets and monocytes coexisting in the PBMC prep-
arations, and that these antibodies induced a direct inter-
action between platelets and monocytes through Fc
receptors for IgG, FcγRs. In this article, we show a novel
converting mechanism, in which IgG-opsonized platelets
evoke a regulatory cascade of circulating monocytes via




Histopaque1077 for the purification of PBMCs was ob-
tained from Sigma-Aldrich (St. Louis, MO). PE-labeled
mouse anti-human CD14 (clone M5E2) was purchased
from BD Biosciences (San Jose, CA). Allophycocyanin-
labeled mouse anti-human CD16 (3G8), mouse anti-
human CD41 (HIP8), mouse anti-human CD42b (HIP1),
mouse anti-human CD9 (HI9a), and mouse anti-human
CD36 (5-271) were obtained from BioLegend (San Diego,
CA). Mouse anti-human CD32 (IV.3) was obtained from
StemCell Technologies (Vancouver, Canada). F(ab’)2 of
the anti-human CD41 and isotype control mAbs were
prepared using a Mouse IgG1 Fab and F(ab’)2 Preparation
Kit (Thermo Scientific, Rockford, IL) according to the
manufacturer’s instructions. Other murine mAbs as to hu-
man platelet antigens including #33 anti-human CD61
IgG2a were generated by Medical & Biological Laboratories,
Co., Ltd. (Nagoya, Japan). The characters of several mAbs
are summarized in Additional file 1: Table S1.
Cell sorting and preparation of human platelets
This study was approved by the Ethics Committee of the
Tohoku University Graduate School of Medicine and per-
formed in accordance with a statement on ethical princi-
ples for medical research involving human subjects made
in the Declaration of Helsinki. Cryopreserved human
PBMCs were obtained from Cellular Technology Ltd.
(Shaker Heights, OH). Frozen PBMCs were rapidly thawed
in a water bath at 37°C, washed and resuspended in RPMI
1640 medium containing 10% FCS. Human PBMCs
and mouse bone marrow (BM) cells were subjected to
immunofluorescence staining, and sort-purified with a
FACSAria III (BD Biosciences). Sort-purified monocytes
were isolated from PBMCs based on forward scatter and
side scatter characteristics and CD14 expression. The data
were analyzed with FACS Diva (BD Biosciences) and
FlowJo (Tree Star, Inc., Ashland, OR) software.For the isolation of platelets, peripheral blood from
healthy donors was drawn into tubes containing acid cit-
rate dextrose, and a crude platelet-rich plasma fraction
was isolated from the whole blood by centrifugation at
230 × g for 15 min at room temperature (RT). For the
purification of platelets, the crude platelet-rich plasma
fraction was centrifuged at 1,600 × g for 15 min at RT,
and the pelleted platelets were resuspended carefully
in the original blood volume of RPMI 1640 medium
containing 10% FCS. The purified platelet preparation
contained about 1 × 105 counts of platelets/μl. The con-
centration differed from one preparation to another mainly
due to the various donors (data not shown), and we used
the purified platelet preparations for experiments without
further adjustment. For the preparation of paraformalde-
hyde (PFA)-fixed platelets, purified platelets were treated
with 1% PFA for 10 min at RT, and then washed with PBS
three times.
Cell cultures and LPS stimulation
Human PBMCs and sort-purified monocytes suspended
in RPMI 1640 medium supplemented with 10% FCS
were seeded onto a 96-well round-bottom plate (Greiner
Bio-one, San Diego, CA), and then stimulated with 1 μg/ml
LPS or 100 μg/ml poly(I:C) for 6–48 h in the presence or
absence of human platelets and anti-platelet mAbs. For the
FcγR-blocking experiments, anti-human CD32 (IV.3) or
anti-human CD16 (3G8) mAbs were added to the wells to
a final concentration of 1 μg/ml. Mouse BM cells were
collected from femur and tibia bones, and suspended in
RPMI 1640 medium supplemented with 10% FCS. Mouse
BM-derived macrophages were obtained by culturing BM
cells for 6–7 days in the presence of 20 ng/ml recombin-
ant mouse M-CSF (PeproTech, Rocky Hill, NJ). Mouse
BM cells and BM-derived macrophages were seeded onto
a 96-well round-bottom plate, and then stimulated with
0.01–1 μg/ml LPS for 24 h in the presence or absence of
human platelets and anti-platelet mAbs.
Transwell experiments
Human PBMCs or mouse BM cells were seeded at 2 × 105
cells/well into the lower chamber of a 24-well plate (Grei-
ner Bio-one). Human platelets were cultured in the lower
chamber directly in contact with the target cells or in the
upper chamber separated from the target cells by a 0.4-μm
pore membrane (Greiner Bio-one), which allows diffusion
of small molecules, such as cytokines, but not platelets.
Cells were stimulated with LPS for 24 h in the presence of
anti-platelet mAbs and the culture supernatants were col-
lected for measurement of cytokine production.
ELISA
ELISAs were performed to measure human IL-1β, hu-
man IL-10, human IL-12, mouse IL-6, mouse IL-10, and
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Human IL-10 ELISA Ready-SET-Go!, Human IL-12 ELISA
Ready-SET-Go! (eBioscience, San Diego, CA), Mouse IL-6
ELISA MAX standard, Mouse IL-10 ELISA MAX stand-
ard, and Mouse IL-12 ELISA MAX standard, respectively
(BioLegend). All ELISAs were performed using 96-well
half-area microplates (Greiner) according to the manufac-
turer's directions.
Mice
C57BL/6 (B6) mice were purchased from Charles River
(Tokyo, Japan) and CLEA Japan (Tokyo, Japan). FcRγ−⁄−
mice [17], Fcgr2b−⁄− mice [18], and Fcgr3−⁄− mice [19] were
backcrossed to B6 mice for 16, 22, and 6 generations, re-
spectively. Mice were maintained and bred in the Animal
Facility of The Institute of Development, Aging and
Cancer, Tohoku University, an environmentally controlled
and specific pathogen-free facility, according to guide-
lines for experimental animals defined by the University,
and animal protocols were reviewed and approved by the
Animal Studies Committee of the University. All experi-
ments were performed on 8- to 12-week-old male and fe-
male mice.
LPS-induced peritonitis
Mice were injected intraperitoneally with LPS at 5 mg/
kg body weight. Anti-CD61 mAb, N6E4, or the isotype-
matched control was intravenously administered 1 h be-
fore LPS challenge. Mice were sacrificed 3 h after LPS
treatment, and then serum was collected.
Statistical analysis
Statistical analysis was performed using Microsoft Excel
for Mac 2011 software version 14.2.3 (Microsoft Corp.,
Seattle, WA, USA). Data are displayed when appropriate as
means ± SD. Data were compared for statistical differences
using Welch's t-test. P values are shown in the relevant fig-
ures. P < 0.05 was considered as statistically significant.
Results
Platelet antibodies augment IL-10 release from peripheral
blood monocytes
The addition of anti-human CD61 (integrin GPIIIa)
(Additional file 1: Table S1) or anti-CD41 (GPIIb) mono-
clonal IgG to a PBMC preparation in the presence of
LPS or poly(I:C) was found to be stimulatory as to the
release of IL-10, but inhibitory as to production of IL-1β
and IL-12 (Figure 1A,B). This cytokine modulation in
monocytes was reminiscent of that in regulatory (or al-
ternatively activated/M2) macrophages [1,14,15], in that
macrophages were stimulated with a TLR ligand and
IgG-ICs. In our assay system, the cytokine modulation
required a direct interaction between the sorted mono-
cytes and IgG-bound platelets, as verified on transwellassaying (Figure 1C). Monoclonal IgG molecules, which
could avidly bind to platelet-surface antigens, such as
CD9, CD36 (GPIIIb/IV), CD42b (GPIb) and CD226, were
also able to augment IL-10 and to reduce IL-1β release as
well (Additional file 1: Figure S1A–C). We concluded that
the increased IL-10 release from monocytes is due to the
direct association with IgG-bound platelets.
IgG-bound platelet-induced regulatory response is
mediated by FcγRII on monocytes
We speculated that the IgG-bound platelet-induced
regulatory response is mediated by Fc receptors for IgG
(FcγRs) expressed on monocytes because they robustly ex-
press several types of FcγRs including activating type recep-
tors FcγRIIA and FcγRIIIA as well as a unique inhibitory,
FcγRIIB [20-22]. Vice versa, monocytes opsonized with IgG
can also serve as a target for FcγRIIA uniquely expressed
on human platelets. This notion was partly verified by our
data shown in Figure 2A, in that the removal of the Fc
portions of mAbs targeted to human CD41 attenuated
the IgG-bound platelet-induced regulatory response.
In addition, an FcγRIIA/B-blocking antibody, IV.3, attenu-
ated IL-10 and restored IL-1β (Figure 2B), indicating that
FcγRIIA/B on monocytes are involved in this response
and that FcγRIIA on platelets could also play a role.
Human peripheral blood circulating monocytes are
classified into two types, CD14++CD32(FcγRIIA/
B)+CD16(FcγRIIIA)− cells, which correspond to "classical
monocytes" in mice, and CD14+CD32+CD16+ cells, which
correspond to murine "non-classical or resident mono-
cytes" [14,21,23,24], the former comprising the majority
(80–90%) in human peripheral blood. Classical monocytes
are those that infiltrate acute inflamed tissues in response
to chemokines, whereas non-classical monocytes are as-
sumed to infiltrate normal tissues and to contribute to
homeostasis. With FcγR expression on these cells, it is
expected that both the CD32+ classical and CD16+ non-
classical type monocytic populations mediate the IgG-
bound platelet-induced regulatory response, although a
major mediator would be the classical ones due to their
abundance in blood. To test this, we sort-purified the
major CD14++CD16− and minor CD14+CD16+ popula-
tions from a peripheral blood sample, confirmed their
FcγRIIA/B expression (Figure 2C), and then measured the
IgG-bound platelet-induced regulatory response activity of
each monocytic population. We found that the classical
monocytes mediated a much more robust IL-10 response
than non-classical monocytes did, which was attenuated
by IV.3, an FcγRIIA/B blocking mAb (Figure 2D upper).
Down-modulation of IL-12 was evenly observed both in
the classical and non-classical monocytes, which was also
attenuated by IV.3 (Figure 2D lower). Blocking effect of
the mAb 3G8, an FcγRIIIA/B blocker, was not evident.
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Figure 1 IgG-opsonized platelets augment IL-10 release but decrease proinflammatory cytokine release from monocytes via their direct contact.
(A) A crude PBMC preparation was stimulated with LPS or poly(I:C) in the presence of anti-human CD61 mAb or isotype-matched control (cIg).
The IL-10, IL-1β, and IL-12 p40 levels in the culture supernatants collected at different time points were determined by ELISA. (B) A crude PBMC
preparation was stimulated with LPS in the presence of an anti-CD61 or anti-CD41 mAb or isotype control (cIg). The IL-10 and IL-12 levels in the
culture supernatant after 24 h were determined by ELISA. Blank (−) indicates cells with no antibody or stimulator for monitoring spontaneous
production of cytokines. (C) Transwell assaying of cytokine production. Sort-purified monocytes were stimulated with LPS in the presence or
absence of platelets and an anti-CD61 mAb. The bottom chamber contained monocytes or was left blank, and the upper chamber contained
platelets. Both chambers contained LPS and the anti-CD61 mAb. The IL-10 (left) and IL-1β (right) levels in the culture supernatant were measured
after 24 h. *P < 0.05; **P < 0.01; n.s., not significant.
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IgG-bound platelet-induced regulatory response, albeit we
do not rule out a contribution of non-classical monocytes
and their FcγRIIIA.
Pre-fixed platelets but not plastic microbeads can
mediate regulatory response
Upon activation, platelets release the contents of their α-
granules and up-regulate various cell-surface molecules
such as P-selectin [25]. We wondered if platelet mole-
cule(s) newly induced upon binding with anti-integrin IgG
could be involved in the IgG-bound platelet-induced regu-
latory response, in addition to the constitutively expressed
FcγRIIA and integrins. To examine this, we first fixed
platelets with paraformaldehyde and then subjected them
to the assaying. As shown in Figure 3A, the pre-fixed
platelets mediated IL-10 augmentation, albeit the IL-10
level was lower than that induced by intact platelets,suggesting that molecules induced upon IgG binding, if
any, are not indispensable for the response. We also won-
dered if plastic microbeads coated with IgG could mimic
anti-integrin IgG-coated platelets. To examine this, we
coated trinitrophenylated (TNP) polystyrene microbeads
with anti-TNP IgG, whose robust binding to the beads
was confirmed by flow cytometry (data not shown), and
then subjected them to assaying. We found that IgG-
coated microbeads of different diameters (1–4.5 μm) did
not show a consistent IL-10 response (Figure 3B). We also
tested if lymphocytes among PBMCs can mimic platelets
because lymphocytes are weakly positive for integrin ex-
pression (Additional file 1: Figure S1A), and observed that
these cells did not stimulate IL-10 or inhibit IL-12 release
(Figure 3C). Collectively, these results suggest a specific
role of platelets in the regulatory response, which cannot
be played by plastic particles or lymphocytes, and the
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Figure 2 FcγRs mediate IgG-bound platelet-induced regulatory response in human peripheral blood circulating monocytes. (A) PBMCs were
stimulated with LPS in the presence of whole IgG of an anti-CD41 mAb or an equimolar amount of the F(ab’)2 fragment, and then the
production of IL-10 and IL-1β was measured after 24 h. Blank (−) indicates cells with no antibody or stimulator for monitoring spontaneous
production of cytokines. Data are shown as means for triplicate samples ± SEM. The results are representative of more than three independent
experiments with similar results. *P < 0.05; **P < 0.01; n.s., not significant. (B) FcγRII mediates IgG-bound platelet-induced regulatory response.
PBMCs were incubated with an FcγRIIA/B-blocking mAb (IV.3), and then stimulated with LPS in the presence of an anti-CD61 or anti-CD41 mAb or its
cIg. Data are shown as means for triplicate samples ± SEM. The results are representative of more than three independent experiments with similar
results. *P < 0.05; **P < 0.01. (C) Robust FcγRIIA/B expression on circulating CD14++CD16− and CD14+CD16+ monocytes. The monocytes were
sort-purified from human PBMCs and tested for their CD32 (FcγRIIA/B) expression. (D) Sorted CD14++CD16− and CD14+CD16+ monocytes
were treated with an anti-CD61 mAb in the presence of CD32 (FcγRIIA/B)- or CD16 (FcγRIIIA/B)-blocking mAb, IV.3 or 3G8, respectively, or
an isotype control, and then stimulated with LPS in the presence of human platelets. The IL-10 and IL-12 levels in the culture supernatants
were measured after 24 h. Data are shown as means for triplicate samples ± SEM. The results are representative of more than three independent
experiments with similar results. *P < 0.05; **P < 0.01; n.s., not significant.
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fective response.
Platelet-induced regulatory response is mediated by
activating-type FcγRs also in mouse settings in vitro
To confirm the involvement of FcγRs and other mole-
cules in vitro, and to evaluate the in vivo effect of the
IgG-bound platelet-induced regulatory response, we next
attempted to construct a cross-species setting, in which
human platelets interact with mouse leukocytes, and also
an all-mouse setting. We incubated mouse bone marrow
(BM) cells with human platelets in the presence of LPSand a mouse IgG2a mAb (6E4), which is reactive to both
human and mouse CD61 (Additional file 1: Table S1).
We found this human platelet–mouse BM cell setting
acted as the IgG-bound platelet-induced regulatory re-
sponse in terms of augmentation or inhibition of mouse
IL-10 or IL-6, respectively (Figure 4A). In addition, cul-
turing of mouse BM cells with "mouse" platelets in the
presence of LPS and with 6E4 resulted in the regulatory
response, but not with a mAb (#33) against human CD61,
which does not bind to mouse CD61 (Figure 4B, see
Additional file 1: Table S1), indicating that the IgG-
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Figure 3 Pre-fixed platelets but not plastic microbead particles nor lymphocytes mediate regulatory response. (A) Pre-fixed platelets can mediate
IgG-bound platelet-induced regulatory response. Paraformaldehyde (PFA)-fixed human platelets and sort-purified monocytes were incubated
with an anti-CD61 mAb following LPS stimulation for 24 h. The IL-10 levels in culture supernatants were determined by ELISA. Data are shown
as means for triplicate samples ± SEM. The results are representative of more than three independent experiments with similar results. **P < 0.01.
(B) Plastic microparticles cannot mimic platelets. Anti-TNP-IgG-coated polystyrene microparticles of different diameters (1, 3, and 4.5 μm) were
incubated with mouse bone marrow cells, which were then stimulated with LPS. After 24 h, the IL-10 levels in the supernatants were measured
by ELISA. Data are shown as means for triplicate samples ± SEM. The results are representative of more than three independent experiments with
similar results. *P < 0.05; **P < 0.01. (C) Sorted lymphocytes cannot mimic platelets. Sort-purified monocytes were subjected to the assaying with
sorted lymphocytes or platelets as control in the presence of anti-CD61 mAb and LPS. The IL-10 and IL-12 levels in culture supernatants were
determined by ELISA. Data are shown as means for triplicate samples ± SEM. The results are representative of more than three independent
experiments with similar results. *P < 0.05; **P < 0.01.
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we choose a suitable anti-mouse platelet antibody.
In the human–mouse setting, as shown in Figure 4C,
Ly6G− monocytic cells but not lymphocytes or Ly6G+
granulocytes among mouse BM cells exhibited the re-
sponse in terms of suppression of IL-6 release, and the
cells from FcR common γ subunit (FcRγ)-deficient mice
had lost the ability of the response, suggesting that FcRγ-
associating, activating-type FcγRs are involved. Mouse
BM-derived cultured macrophages also showed the IgG-
bound platelet-induced regulatory response, and againFcRγ was necessary but a unique inhibitory FcγR, FcγRIIB,
was found to be dispensable for this effect (Figure 4D). Our
additional examinations revealed that FcRγ-associating
FcγRIII is involved in the regulatory response when a
murine IgG1 anti-human platelet antibody was employed
(Additional file 1: Figure S2), while an IgG2a antibody still
induced the response even in the absence of FcγRIII, sug-
gesting other activating FcγRs, such as FcγRI and FcγRIV,
are also involved. Collectively, in the mouse setting
in vitro, the IgG-bound platelet-induced regulatory re-
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Figure 4 Activating-type FcγRs but not FcγRIIB mediates IgG-bound platelet-induced regulatory response in a mouse monocyte setting in vitro.
(A) Mouse bone marrow (BM) cells were incubated with LPS in the presence of human platelets and an anti-human/mouse CD61 mAb (6E4), and
then the production of IL-10 and IL-6 was assessed after 24 h. *P < 0.05; **P < 0.01. (B) Mouse BM cells were incubated with LPS in the presence
of "mouse" platelets and anti-human/mouse CD61 mAb 6E4 or anti-human but not -mouse CD61 mAb #33 or cIg, and then the production of
IL-10 (left) and IL-6 (right) was assessed after 24 h. #33 mAb did not cause the regulatory response in this all-mouse setting. **P < 0.01; n.s., not
significant. (C) Neither granulocytes nor lymphocytes mediate regulatory response. Gr1+Ly6G− monocytic, Gr1+Ly6G+ granulocytic and
Gr1−Ly6G− lymphoid cells were sorted from BM cells of wild-type B6 or FcRγ-deficient mice, and stimulated with LPS in the presence of "human"
platelets and 6E4 or cIg. IL-6 was measured 24 h after stimulation by ELISA. **P < 0.01; n.s., not significant. (D) BM-derived cultured macrophages from
wild-type, FcRγ-deficient or FcγRIIB-deficient mice were treated with anti-CD61 mAb 6E4 and stimulated with LPS in the presence of human platelets.
The IL-10 and IL-6 levels in the culture supernatants were measured after 24 h. Blank (−) indicates cells with no antibody or stimulator for monitoring
spontaneous production of cytokines. Data are shown as means for triplicate samples ± SEM. The results are representative of more than three
independent experiments with similar results. *P < 0.05; n.s., not significant.
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in vivo model
We next examined if IgG-bound platelet-induced regula-
tory response occurs in in vivo settings. We determined
the cytokine levels in serum of a systemic septic shock
model, in which mice were administered intraven-
ously an anti-CD61 mAb and subsequently a sub-
lethal dose of LPS intraperitoneally. As shown in
Figure 5A, we observed that IL-10 was up-regulated
while IL-6 was not affected, compared to in micethat received isotype-matched control antibodies, sug-
gesting that IgG-bound platelet-induced regulatory
response occurs, at least partly, in terms of IL-10 up-
regulation. We verified again in this in vivo model
that FcRγ-associating FcγRs but not FcγRIIB play a
significant role in the response (Figure 5B). We do not
know why a proinflammatory cytokine, IL-6, did not
decrease in this in vivo setting, but additional IL-6-
producing cells other than monocytes at the periphery
might be involved.
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Figure 5 Augmented serum IL-10 in a murine in vivo setting. (A, B) Wild-type B6 mice were administered intravenously an anti-human/mouse
CD61 or isotype control mAb and subsequently with LPS intraperitoneally. The IL-10 and IL-6 levels in serum samples collected at 3 h after LPS
stimulation were measured by ELISA (A). IL-10 upregulation in sera was observed also in FcγRIIB-deficient but not FcRγ-deficient mice (n = 4 mice per
group) (B). The results are representative of more than three independent experiments with similar results. *P < 0.05; **P < 0.01; n.s., not significant.
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In this study, we described a novel, IL-10 inducing,
switching mechanism converting peripherally circulating
monocytes to regulatory cells, involving IgG-bound plate-
lets and activating-type FcγR (Figure 6). Platelets are gen-
erally known as a key player in blood clotting and wound
repair processes, namely, the orthodox role of platelets in
platelet-rich plasma or PRP therapy. In addition, platelets
are an important accelerator of inflammation by releasing
proinflammatory cytokines and chemokines, as well as by
binding to various effector leukocytes including mono-
cytes and neutrophils [1,3,26]. In an autoimmune arthritis
animal model, for example, it has been demonstrated that
platelets can amplify inflammation by producing micro-
particles derived from their own, which bind to activated
polymorphonuclear leukocytes, thereby eliciting cytokine
responses of synovial fibroblasts via interleukin IL-1 [27].
This binding process is dependent on glycoprotein IV or
GPIV on platelets, and on the microparticles and collagen
on inflammatory leukocytes [27]. Also, platelets activated
by thrombin or other agonists can bind to monocytes
in a P-selectin-dependent manner thereby inducing the
production of proinflammatory cytokines by those cells.
Importantly, however, when platelets are once acti-
vated, subsequent inflammatory responses induced by
them should be adequately suppressed so as not toevoke excessive inflammation harmful for tissues. One
mechanism for regulation of such platelet-initiated in-
flammation will be engulfment and degradation of the
platelets by monocytes/macrophages. In this study, we
found that platelets have a potential to convert activated
monocytes/macrophages to regulatory cells when they are
complexed with anti-platelet IgG molecules, which could
be another mechanism for regulation of platelet-initiated
inflammation.
Regulatory (or alternatively activated/M2) macrophages
[15,23,24,28] are induced in vitro or in some infection
models in vivo by small ICs such as OVA and anti-OVA
antibodies [29], or particulate ICs such as IgG-opsonized
sheep erythrocytes [14] or IgG-bound pathogen Leish-
mania major [16], in addition to by TLR stimulation with
ligands such as LPS or live Listeria. These preceding stud-
ies have established the idea that when macrophages are
activated with TLR and FcγRs concomitantly, they become
"alternatively" activated to give rise to regulatory ones
showing upregulated IL-10 production [14,29], rather than
to "classically" activated ones producing inflammatory cy-
tokines and chemokines such as IL-12 and CXCL9–11
[23,30]. Regulatory macrophages can be induced during
the later stages of adaptive immune responses, in which
antigen-specific IgG molecules are abundantly produced,












Figure 6 A proposed scheme for IgG-bound platelet-induced
regulatory response. In IgG-bound platelet-induced regulation, a
reciprocal interaction of IgG-opsonized platelets with monocytes
via FcγRs constitutes the main and sub pathways. The main
pathway is mediated by platelet surface molecules such as integrins,
and IgG and activating-type FcγRs including FcγRIIA/IIIA/I on
monocytes. The sub pathway includes monocyte-surface molecules
such as integrins, and IgG and FcγRIIA on platelets. We do not rule
out the potential involvement of a platelet-surface molecule(s), which
contributes to the interaction with monocytes. Since platelets are
much smaller than monocytes, it is likely that these pathways for a
monocyte will be attained with multiple platelets.
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In this study, it is suggested that IL-10-producing regula-
tory monocytes/macrophages could be induced by employ-
ing anti-platelet IgG in place of antigen-specific antibodies.
A defect in IL-10 production could be linked to certain
autoimmune and inflammatory diseases [6,11]. Therefore,
in addition to understanding of the molecular mechanism
that regulates the expression of this cytokine, therapeutic
strategies to augment IL-10 production in inflammatory
and autoimmune diseases have been attracting much at-
tention. Our current finding that once platelets become a
component of ICs with anti-integrin IgG, thereby target-
ing FcγRs on monocytes/platelets, could be a useful strat-
egy for engineering IgG reagents that can interact with
platelets and monocytes with suitable avidity so as to
interact with these particles/cells and FcγRs, and to stimu-
late the IL-10-inducing pathway in monocytes. It is not
known currently why IgG-platelets cannot be replaced
with IgG-coated plastic microparticles in terms of con-
verting monocytes to regulatory ones. We speculate thatsome undefined molecules on platelets other than integ-
rins and FcγRIIA are necessary for efficient interaction
with, and stimulation of, monocytes. Identification of such
participating molecules for the platelet–monocyte inter-
action will enable us to develop a more efficient means of
anti-inflammation than the IgG-opsonized platelets exam-
ined in this study.
The molecular nature and the immune-activating roles
of FcγRIIA and other activating-type FcγRs have been
extensively studied [21]. Transgenic mice expressing hu-
man FcγRIIA are highly susceptible to tissue damage by
pathological antibodies in ICs, implicating FcγRIIA as a
central mediator of inflammation in humans [2,31-33].
In contrast to the wealth of knowledge on FcγRIIA’s role
as an inflammatory mediator, its anti-inflammatory role
has not been studied sufficiently. Our present study has
indicated FcγRIIA’s regulatory role in monocyte activation
as well as a supporting role of this receptor on platelets,
giving rise to regulatory cells via interaction with IgG-
opsonized platelets. In addition to IL-10-mediated anti-
inflammation, targeting to FcγRIIA and other FcγRs has
also been developed to treat inflammation and cancer
[21]. The latter include recombinant soluble decoy FcγRs
as competitive blockers, and anti-receptor mAbs, syn-
thetic peptides, Ig mimetics and small chemicals as FcγR
blockers. Our present observations change our idea of ac-
tivating FcγRs from inflammatory to regulatory receptors.
Conclusions
Our findings of the IgG-bound platelet-induced conver-
sion of monocytes to regulatory cells open a new avenue
for the development of IL-10-inducing therapeutic strat-
egies for inflammation, autoimmune diseases and cancer.Additional file
Additional file 1: Table S1. Specificities and isotypes of monoclonal
IgG antibodies used for IgG-bound platelet-induced regulatory response
or its blocking in this study. Figure S1. Platelet-reactive IgG antibodies
can evoke the response. (A–C) Antibodies binding avidly to platelets can
augment IL-10 release and reduce IL-1β. Using a whole PMBC preparation,
the binding activity of each mAb as to platelets was assessed by flow
cytometry (A). Cytokine modulation by mAbs was compared (B), and
the results were summarized (C). Cytokine modulation roughly correlated
with flow cytometric reactivity of mAbs to platelets. Figure S2. Indispensable
FcRγ but not FcγRIIB, and the isotype-dependent nature of IgG-bound
platelet-induced regulatory response. Bone marrow (BM)-derived cultured
macrophages from wild-type (WT), FcγRIII-, FcγRIIB- or FcRγ-deficient mice
were treated with an anti-human CD41 or CD42b, or anti-human CD9 mAb
(isotype, IgG1) or anti-human CD36 mAb (IgG2a), and then stimulated with
LPS in the presence of human platelets. The IL-10 (upper) and IL-6 (lower)
levels in the culture supernatants were measured after 24 h. Data are shown
as means for triplicate samples ± SEM. The results are representative of more
than three independent experiments with similar results. **P < 0.01.Abbreviations
BM: Bone marrow; FcγR: Fc receptor for IgG; FcRγ: Fc receptor common γ
subunit; IC: Immune complex.
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